Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800
ADVERTISEMENT The stock surged 20% in early trade to hit a lifetime high of Rs 2,284.80, before paring some gains as the session progressed.
The rally was triggered after the company announced that its step-down, wholly owned subsidiary, Ichnos Glenmark Innovation (IGI), had signed an exclusive global licensing agreement with US-based AbbVie for its experimental cancer drug, ISB 2001.
Commenting on the price action, Anuj Gupta, Director at Ya Wealth Global Research, said the stock appears poised for a continued rally.'Strong technical structure supported by substantial volumes bodes well for further upside. We expect it to rise further, especially as the Trump tariff stance on pharma is seen as positive for US-based pharmaceutical brands,' he said.Gupta added that Glenmark has a significant presence in the US pharmaceutical market.
ADVERTISEMENT In his view, Glenmark Pharma shares may test levels of Rs 2,600 to Rs 2,800 in the short term, implying a potential upside of 29% from the current level of Rs 2,172.80. He sees strong support at Rs 1,800 and recommends a buy-on-dips strategy.Nilesh Jain, Vice President – Equity Research (Technical and Derivatives) at Centrum Broking, echoed a similar sentiment, noting that the stock's structure remains positive on charts despite Friday's sharp rally. While he does not currently see an ideal risk-to-reward setup, he believes a near-term target of Rs 2,200 is achievable.
ADVERTISEMENT The stock has emerged from a breakaway gap, Jain added — a technical pattern marked by a breakout accompanied by a wide price gap, often signaling the start of a strong uptrend. According to him, Rs 2,100 would be a more favourable level to enter the stock.Meanwhile, brokerage Motilal Oswal sees a 28% upside from Thursday's closing price of Rs 1,904 and has reiterated its 'Buy' rating on Glenmark Pharma. 'We assign a 27x 12-month forward earnings multiple to arrive at a sum-of-the-parts (SOTP) valuation of Rs 2,430,' the brokerage said, adding that the AbbVie deal signals a new era for the company.
ADVERTISEMENT About ISB 2001 ISB 2001, currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, will be jointly developed under the agreement. AbbVie will hold exclusive rights to develop, manufacture, and commercialise the drug in North America, Europe, Japan, and China. Glenmark will retain rights for emerging markets, including Asia (excluding Japan and China), Latin America, Russia/CIS, the Middle East, Africa, Australia, New Zealand, and South Korea.Under the agreement, IGI Therapeutics SA — a subsidiary of Ichnos Glenmark Innovation — will receive a $700 million upfront payment and is eligible for up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales.The US FDA granted ISB 2001 orphan drug designation in July 2023 and fast-track status in May 2025 for treating relapsed or refractory multiple myeloma.
ADVERTISEMENT 'Multispecifics like trispecific antibodies represent a new frontier in immuno-oncology,' said Roopal Thakkar, EVP and CSO at AbbVie. 'This partnership reflects our commitment to advancing novel therapies for patients with multiple myeloma, where unmet needs remain.'Cyril Konto, MD, President and CEO of IGI, added:'This agreement marks a defining milestone in IGI's journey. Our partnership with AbbVie accelerates ISB 2001's path to patients and strengthens our focus on the next generation of BEAT®-enabled assets.'
(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
18 minutes ago
- Business Standard
Senior living rents touch ₹1 lakh, retirement homes valued at $8.4 billion
India's senior living segment is set for a massive transformation, with investment potential between $4.8 billion and $8.4 billion ( Rs 410–720 billion) over the next five years, according to Savills India's latest report, Living the Years That Count. The surge is being driven by India's rapidly ageing population, projected to reach 21% of the total population by 2050, and increasing demand for organised, health-integrated retirement communities. India currently has over 155 million people aged 60+, a number expected to double by mid-century. Unlike the past where old-age homes were seen as last resorts, today's seniors are demanding autonomy, wellness, community engagement, and access to medical care—without sacrificing comfort. Developers are responding by creating purpose-built environments focused on both care and lifestyle. Demand, Design, and Dollars According to the report: Independent living units dominate the market with a 90–95% share. Monthly rentals for senior living residences range between Rs 25,000 to Rs 1 lakh, depending on the level of care and amenities. Outright purchase prices for 1–2 BHK units range from Rs 45 lakh to Rs 2 crore in metro cities, and Rs 25 lakh to Rs 80 lakh in non-metro cities. Leading operators like Antara, Columbia Pacific, Ashiana Housing, Primus, and Athulya are developing models across the spectrum—independent, assisted, and memory care. Interestingly, 34% of under-construction senior living projects are in non-metro cities like Coimbatore, Vadodara, and Goa, where property is more affordable and lifestyle factors like air quality and community ties are better. According to Savills: South India leads with 68% of senior living projects. Cities like Dehradun, Coimbatore, Pune, and Kodaikanal rank highest in terms of accessibility to healthcare and transit, making them ideal retirement destinations. Global Inspiration, Local Innovation The report draws on global best practices from the US, Japan, Australia, UK, and New Zealand, where integrated models and policy support have made senior living more inclusive. In India, however, the focus is still skewed toward premium housing. Experts suggest rental and lease-based models could help make senior living more accessible for middle-income retirees. Policy Push and Investment Appeal India's senior living sector remains under-regulated. The report calls for: GST relief on senior living services Priority sector status Subsidised loans and viability gap funding A dedicated regulatory framework Strategic investments are already flowing in: Max India: $25.6 million Rainmatter & Gruhas: $20 million Morgan Stanley India Infra Fund: $11 million Even large developers like Godrej Properties are entering via partnerships, with Pioneer Urban launching IGBC Platinum-certified projects. The Opportunity Ahead Savills outlines three market scenarios: Conservative: 1.25% of seniors adopt structured living → USD 4.8 bn investment Moderate: 1.5% adoption → USD 6.5 bn investment Optimistic: 1.75% adoption → USD 8.4 bn investment 'Bharat is leading the way in shaping the future of senior living, with tier-2 cities driving the shift through affordable housing, healthcare, and thoughtfully designed communities. With over USD 8 billion in projected investment and the Government's growing policy push, this is one of India's most transformative infrastructure opportunities with the path forward focused on building inclusive ecosystems that enable dignified and comfortable ageing,' said Arvind Nandan, Managing Director, Research & Consulting, Savills India.
Time of India
18 minutes ago
- Time of India
You can buy a product instantly, then why is disposal difficult?
GREEN POWER: Radha Goenka talks of a future green corridor in Mumbai The climate and sustainability sessions threw up compelling questions that look ed at the progressive thinking and action on the ground. 'India's Waste to Energy success story is that every drop of petrol produced is blended with 20per cent ethanol, much of which comes from agri waste. This has saved us Rs 1.1 trillion on crude imports and helped mitigate 544 lakh metric tonnes of CO2,' said SSV Ramakumar of AM Green. Wilma Rodrigues, of Saahas zero waste said: '60per cent of dry waste is low-value plastic that ends up in landfills. When properly sorted, it can be sent to W2E plants (as feedstock).' Pranshu Singhal of Karo Sambhav said while schemes such as the extended producer responsibility were sound, the question of financing waste collection and recycling remained unresolved. 'You can buy a product instantly, why is disposal difficult?' Public policy can't be implemented without investment, said Srestha Banerjee of iFOREST. Policy support and financial resource mobilisation are both needed to develop capacity to scale sustainable solutions, she said. 'Philanthropy can fund experimental climate solutions. As innovative capital, it fills the space between govt and business,' said Radha Goenka of RPG Foundation, whose organisation supported the transformation of a public garden into an urban forest called The Nest in Mumbai, and plans to use it as a prototype to create a green corridor in the city. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giá vàng đang tăng mạnh trong năm 2025 — Các nhà giao dịch thông minh đã tham gia IC Markets Tìm hiểu thêm Undo While sustainable solutions need govt and corporate support, communities are no less capable of driving change, said Bipin Odhekar of Marico adding: 'What's important is to build conviction in stakeholder communities.' Aarti Khosla of Climate trends, said: 'There's a lopsided focus on mitigation. We need adaptive solutions to changing weather and to address declining agricultural production due to rising heat, for instance.' Conventional thinking around environment versus development needs to be challenged, insisted Geetanjoy Sahu, Dean of TISS. Shilpashree Muniswamappa of Colgate-Palmolive India, said, 'People don't necessarily buy to benefit the planet; they buy what saves them money.', adding that consumers shouldn't have to pay a premium for sustainable products.
Time of India
18 minutes ago
- Time of India
Tamil Nadu: MBBS course in self-financing colleges to cost Rs 1.5 lakh a year more; revised fee structure out
CHENNAI: MBBS fees for 2025 under management quota in self-financing colleges will increase by Rs 1.5 lakh to Rs 15 lakh a year, and the fee for NRIs will go up by Rs 2.5 lakh to Rs 27 lakh, according to the revised fee structure released by TN Directorate of Medical Education. The fee for students joining under the govt quota will remain unchanged, while those joining state private universities under the NRI quota will pay Rs 30 lakh -Rs 60,000 more compared to previous years. The proceedings of the committee on the fixation of fees in respect to self-financing professional colleges, chaired by Justice Pongiappan, which sets fees for undergraduate and postgraduate medical and dental courses, released on Monday said that the prescribed fee structure will be effective for students admitted for admissions in 2025, 2026 and 2027. Tamil Nadu has an annual admission capacity of 11,700 MBBS seats, with 5,050 seats in govt medical colleges. There are 22 self-financing private medical colleges and four private universities. You Can Also Check: Chennai AQI | Weather in Chennai | Bank Holidays in Chennai | Public Holidays in Chennai Non-minority institutions in self-financing colleges and state private universities share 65% of seats for admission under the govt quota, and minority institutions share 50% of seats. Admission to all seats in self-financing colleges and state private universities are done by the state selection committee. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Cách giao dịch ETH/USD mà không cần nắm giữ Ether IC Markets Tìm hiểu thêm Undo NRI lapsed seats removed The biggest change, however, is the elimination of the 'NRI lapse' category. The NRI lapsed seats - a category created to fill in non-NRI candidates alongside the management quota in self-financing medical/dental colleges and state private universities - have been removed. The selection committee will transfer NRI seats vacant after three rounds of counselling to the common pool in the management category, allowing Indian students to take these seats at a cost that is at least 30% lower. Until 2024, self-financing colleges were allowed to collect Rs 24.5 lakh as NRI fees. Colleges set aside 15% of the seats for the NRI category. If these seats were not filled, they were converted into NRI lapse seats, for which Rs 21.50 lakh was collected as annual tuition fee. Meanwhile, the committee has permitted institutions to collect an additional Rs 60,000 as development fee and has directed managements to cover all the students under a students' group insurance scheme. "The above fee does not include hostel, transport and mess charges, which are optional for students. Institutions are directed to submit the details of the above fee to the selection committee well in advance before counselling," the committee said. The panel directs that the institution shall not collect or levy any other recurring or non-recurring fee, including capitation, it said.
